Fortis Healthcare Ltd.
NSE: FORTISFortis Healthcare Ltd.: A 30-second snapshot
Fortis Healthcare trades at 948.85, roughly flat over the past three months (+0.03%) though up 12.24% over the past year and 13.99% below its 52-week high. Trailing PE of 68.68x sits well above its own forward PE of 40.46x and most sector peers, while ROE of 11.01% has not crossed 15% in any of the 5 years on record. Mean analyst rating across 20 analysts stands at 1.45 on a 1-5 scale (lower = more constructive), and recent news flow around the Q1 earnings call, dividend record date, and hospital network expansion in Odisha has skewed positive (4 positive, 4 neutral, 0 negative of 8 items).
P/E
68.7
Forward P/E
40.5
ROE
+11.0%
Debt / Equity
34.15
Profit Margin
+11.4%
Div. Yield
+0.1%
5Y ROE > 15%
0/5
5Y FCF > 0
4/5
Quality
65/100
News
8 headlines · 4 positive · 0 negative
Fortis Healthcare Schedules Q1 Earnings Call For August 7 - Sahi
Sahi
Fortis Healthcare sets dividend record date, outlines TDS norms - scanx.trade
scanx.trade
Fortis Healthcare enters Odisha with 300-bed Cuttack hospital under O&M model - Moneycontrol.com
Moneycontrol.com
Fortis Healthcare Appoints Vijender Singh as Agilus Diagnostics MD & CEO - HDFC Sky
HDFC Sky
Fortis healthcare reappoints Ashutosh Raghuvanshi as MD for two more years - Business Standard
Business Standard
Recent context
- ·Fortis Healthcare scheduled its Q1 earnings call for August 7, 2026 (Sahi, Jul 30).
- ·The company set a dividend record date and outlined TDS norms (scanx.trade, Jul 21), and reappointed Ashutosh Raghuvanshi as MD for two more years (Business Standard, Jul 8).
- ·Fortis expanded into Odisha with a 300-bed hospital under an O&M model in Cuttack (Moneycontrol, Jul 3), alongside a new MD & CEO appointment at Agilus Diagnostics (HDFC Sky, Jul 20).
Strengths
- +5-year earnings growth of 44.3% has outpaced 5-year revenue growth of 17.8% over the same period.
- +Free cash flow was positive in 4 of the years measured.
- +Quality score of 47/100 ranks 2nd of 6 sector peers, behind Sun Pharma (56) and ahead of Apollo (44), Max Healthcare (37), Cipla (28), and Dr. Reddy's (4).
- +Mean analyst rating of 1.45 across 20 analysts (1-5 scale, lower = more constructive) alongside predominantly positive-to-neutral recent news flow (4 positive, 4 neutral, 0 negative of 8 items).
Weaknesses
- −ROE of 11.01% has not exceeded 15% in any of the 5 years measured, with a consistency score of 49/100 and a debt-to-equity trend flagged as rising (current ratio approximately 0.34x, from the reported metric of 34.15).
- −Trailing PE of 68.68x is the second-highest among 6 sector peers, well above its own forward PE of 40.46x and above Sun Pharma (41.62x), Cipla (35.37x), and Dr. Reddy's (28.90x).
- −Price trades below its 50-day moving average (948.85 vs 959.95), with 3-month price change essentially flat (+0.03%) versus +12.24% over the trailing year, and sits 13.99% below its 52-week high.
- −The technical section's current price carries no explicit as-of timestamp, limiting confirmation of how current it is relative to the August 1, 2026 run date.
Open questions
- ?What is driving the rising debt-to-equity trend even though the absolute leverage ratio (approximately 0.34x) remains modest — capacity expansion, working capital, or something else?
- ?Why has ROE stayed below 15% in every year measured despite 44.3% five-year earnings growth — is equity base growth outpacing profit growth, or is this a base-effect from historically low returns?
- ?Does the gap between trailing PE (68.68x) and forward PE (40.46x) reflect earnings estimates already priced in by the market, or room for further re-rating if the growth materializes?
- ?How might the upcoming Q1 earnings call (August 7) and the new Odisha hospital under an O&M model change the revenue and margin trajectory going forward?
Peer comparison: Pharma
Ranks 2 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| FORTIS | Fortis Healthcare Ltd.You're viewing | 68.7 | +11.0% | 47 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.4 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 74.6 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.4 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.9 | +8.8% | 4 |
Technical state
Current price
₹948.85
SMA 50
₹959.95
SMA 200
₹926.27
RSI (14)
47.0 (neutral)
From 52w high
-14.0%
1Y return
+12.2%
3M return
+0.0%
50-DMA
Below
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumROE of 11.01% has not exceeded 15% in any of the 5 years measured, alongside a consistency score of 49/100 and a debt-to-equity trend flagged as rising (current ratio approximately 0.34x, derived from the reported percent-scaled metric of 34.15) — return on capital remains below the 15% threshold even as leverage trends upward.
- mediumTrailing PE of 68.68x is the second-highest among 6 sector peers (only Max Healthcare at 74.58x is higher), well above its own forward PE of 40.46x and above peers Sun Pharma (41.62x), Cipla (35.37x), and Dr. Reddy's (28.90x) — a valuation premium that presumes earnings growth materializes.
- lowPrice of 948.85 sits below the 50-day moving average (959.95) though still above the 200-day average (926.27), is 13.99% below its 52-week high, and 3-month price change is essentially flat at +0.03% versus +12.24% over the trailing 12 months — recent momentum has stalled relative to the 1-year trend.
- lowThe technical section's current price carries no explicit as-of timestamp in the data provided, so its currency relative to the August 1, 2026 run date cannot be independently confirmed.
Cross-section contradictions
- News sentiment skews positive (4 positive, 4 neutral, 0 negative of 8 items) covering the Q1 earnings call, dividend record date, MD reappointment, and Odisha hospital expansion, yet the stock trades below its 50-DMA with a flat 3-month price change (+0.03%) and sits 13.99% below its 52-week high — positive headline flow has not coincided with a re-acceleration in price momentum.
- 5-year earnings growth of +44.3% has not lifted ROE above 15% in any of the 5 years measured, consistent with a mid-range consistency score of 49/100 — reported earnings growth without a corresponding improvement in return on equity.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 1 Aug 2026 · rotates through NIFTY 500 every ~5 days